Unusual side-effects due to clobazam: A case report with genetic study of CYP2C19

Brain and Development

Volumn 26, Issue 1, 2004, Pages 63-66

  Parmeggiani, Antonia ^a   Posar, Annio ^a   Sangiorgi, Simonetta ^a   Giovanardi Rossi, Paola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Benzodiazepines; Clobazam; CYP2C19; Epilepsy; Side effects; Subcontinuous EEG paroxysmal abnormalities

Indexed keywords

CLOBAZAM; CYTOCHROME P450 2C19; DNA;

ANAMNESIS; ARTICLE; BRAIN RADIOGRAPHY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ENURESIS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; LABORATORY TEST; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENT; PHENOTYPE; PSYCHOLOGIC TEST; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0347091761     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0387-7604(03)00074-3     Document Type: Article

References (13)

1. Shorvon S.D. Benzodiazepines-Clobazam. Levy R.H., Mattson R.H., Meldrum B.S. 4th ed. Antiepileptic drugs. 1995;763-777 Raven Press, New York, NY.
2. De Negri M., Baglietto M.G., Battaglia F.M., Gaggero R., Pessagno A., Recanati L. Treatment of electrical status epilepticus by short diazepam (DZP) cycles after DZP rectal bolus test. Brain Dev. 17:1995;330-333.
3. Viani F. Modificazioni psicopatologiche indotte dai farmaci antiepilettici. Lega Italiana Contro l'Epilessia (LICE). Manuale italiano di epilettologia. 1992;1397-1407 Piccin "Nuova Libraria" Padova.
4. Bardy A.H., Seppala T., Salokorpi T., Granstrom M.L., Santavuori P. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev. 13:1991;174-179.
5. Contin M., Riva R., Albani F., Baruzzi A. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 21:1999;604-608.
6. Poolsup N., Li Wan Po A., Knight T.L. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 25:2000;197-220.
7. Goldstein J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 52:2001;349-355.
8. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 269:1994;15419-15422.
9. de Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 46:1994;594-598.
10. Ferguson R.J., de Morais S.M., Benhamou S., et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 284:1998;356-361.
11. Ibeanu G.C., Blaisdell J., Ghanayem B.I., et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 8:1998;129-135.
12. Ibeanu G.C., Goldstein J.A., Meyer U., et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther. 286:1998;1490-1495.
13. Giovanardi Rossi P., Parmeggiani A., Posar A., Scaduto M.C., Chiodo S., Vatti G. Landau-Kleffner syndrome (LKS): long-term follow-up and links with electrical status epilepticus during sleep (ESES). Brain Dev. 21:1999;90-98.